Chlíbek R, Cecetková B, Smetana J, Prymula R, Kohl I
Fakulta vojenského zdravotnictví UO, Hradec Králové.
Epidemiol Mikrobiol Imunol. 2006 Aug;55(3):99-104.
To determine prevalence rates of antibodies against hepatitis A virus (HAV) and hepatitis B virus (HBV) in the general adult male and female population over 40 years of age with no history of viral hepatitis A (VHA) and viral hepatitis B (VHB) who have never been vaccinated against hepatitis and to assess the cost-effectiveness of the pre-vaccination serological screening.
In 2003-2004, a total of 972 persons of three age categories: 41-50 years, 51-60 years, 61 and more years, were screened. Persons with a history of VHA and/or VHB and those who had been vaccinated against hepatitis were not included in the study. The following four indicators were determined from a 5 ml specimen of whole venous blood by electrochemiluminiscence assay: total anti-HAV antibodies, total anti-HBc antibodies, anti-HBs antibodies and HBsAg, as the most suitable markers of experienced hepatitis or previous vaccination.
The prevalence rates of anti-HAV antibodies were lower in females compared to males for all of the three age categories. These antibodies were detected in 16.8%, 52.9% and 77.5% of 41-50-year-olds, 51-60-year-olds and > or = 61-year-olds, respectively. The total prevalence rate for the three age groups was 61.6%. The anti-HBc antibody seroprevalence rates were 1.9%, 5.3% and 6.1%, respectively.
The results show high prevalence of VHA in higher age groups. Such a high seroprevalence of antibodies in nonvaccinated persons with no history of viral hepatitis is suggestive of a very frequent incidence of asymptomatic infection. For this reason, the prevaccination screening of anti-HAV antibodies is cost-effective in the population over 50 years of age but is not justified in persons under 40 years of age. Prevaccination screening for anti-HBc antibodies appears not to be cost-effective regardless of age in view of their low prevalence in the Czech population.
确定40岁以上从未患过甲型病毒性肝炎(VHA)和乙型病毒性肝炎(VHB)且从未接种过肝炎疫苗的成年男性和女性普通人群中抗甲型肝炎病毒(HAV)和抗乙型肝炎病毒(HBV)抗体的流行率,并评估接种前血清学筛查的成本效益。
2003 - 2004年,对三个年龄组(41 - 50岁、51 - 60岁、61岁及以上)的972人进行了筛查。有VHA和/或VHB病史以及已接种过肝炎疫苗的人未纳入本研究。通过电化学发光法从5毫升全静脉血标本中检测以下四项指标:抗-HAV总抗体、抗-HBc总抗体、抗-HBs抗体和HBsAg,作为既往感染肝炎或既往接种疫苗的最合适标志物。
在所有三个年龄组中,女性抗-HAV抗体的流行率均低于男性。在41 - 50岁、51 - 60岁和≥61岁的人群中,分别有16.8%、52.9%和77.5%检测到这些抗体。三个年龄组的总流行率为61.6%。抗-HBc抗体的血清流行率分别为1.9%、5.3%和6.1%。
结果显示高龄组VHA的流行率较高。在无病毒性肝炎病史的未接种人群中如此高的抗体血清流行率表明无症状感染的发生率非常高。因此,对50岁以上人群进行接种前抗-HAV抗体筛查具有成本效益,但对40岁以下人群则不合理。鉴于抗-HBc抗体在捷克人群中的低流行率,无论年龄大小,接种前筛查似乎都不具有成本效益。